A new study has found that fragment 176-191 of the human growth hormone (HGH) molecule is effective in reducing fat, improving muscle recovery, and stimulating bone strength. It also shows promise as a treatment for diabetes.
Fragment 176-191 is a 15-mer synthetic 16AA C-terminus peptide analogue of hGH. According to researchers, the peptide has the potential to enhance fat loss without interfering with the body’s energy homeostasis.
The AA chain is a vital active site in the GH molecule. In fact, it is only about seven to ten percent of the full GH molecule. This fragment 176-191 has been nicknamed the “lipolytic fragment” because it is thought to destroy fat.
The peptide has the ability to stimulate protein synthesis, increase IGF-1 levels, and help improve sleep. Some research suggests that the peptide may also have the potential to reduce blood sugar levels, which can help prevent or treat type 2 diabetes.
The peptide does not cause any serious side effects. Studies have used dosages ranging from five to ten milligrams per kilogram of body weight. These dosages should be given three hours apart and only when the stomach is empty. Currently, no clinical studies have been conducted on the safety of the peptide.
Researches are currently investigating the possible applications of Fragment 176-191 as a treatment for obesity, prediabetes, and diabetes. There is also some interest in the peptide’s effect on fat deposition.
The development of the fragment 176-191 has opened up a new avenue of research into the regulation of human energy homeostasis. Specifically, the peptide offers a glimpse into the role that the adipose tissue plays in fat burning.